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ABSTRACT 
Objective: As of now, the world is struggling with a serious pandemic of disease 2019 Coronavirus (COVID-19), which was emerged from Wuhan in 
China, originated by the novel coronavirus 2019 (SARS-CoV-2). COVID-19 is a viral illness, which is occurring on a large scale in every nation of the 
globe. Symptoms of coronavirus mainly include fever, fatigue, cough, headache, pneumonia and in severe condition, there is respiratory distress. 
The deadly virus alarmed the world to be on high alert as the number of rising cases and the death toll rising as the day passes. 
Methods: We have searched for articles of preference and interest systematically in sources like Google Scholar, PubMed, and other outlets. 
Results: Management in the case of diabetes is really necessary to decrease their mortality. Certain management parameters need to be followed to 
take care of patients suffering from both diseases. 
Conclusion: In this review, we highlighted the role of different medicines like chloroquine, lopinavir, and hydroxychloroquine for the remedy of this 
pandemic. We also discussed the chest Computed tomography functions and Real-time polymerase chain reaction for the screening of the outbreak. 
The center of attention of this review majorly on the care of diabetes throughout the time of the COVID-19 epidemic. 
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INTRODUCTION 
Respiratory disorders are the primary cause of death and morbidity 
and impact the lives of more than a billion people across the world. 
Children and young kids are highly vulnerable [1]. Global health is 
usually enhancing, with lesser persons dying due to infectious 
diseases and thus surviving long enough in many cases to develop 
chronic diseases [2]. Chronic respiratory diseases (CRDs) are 
acknowledged as a crucial source of unintended death in the 
population globally. CRDs are a disease of the airway and the 
additional structure of the lungs adds up to a large formation of 
major illness. Curable long-standing respiratory disease includes 
asthmatic diseases, respiratory allergic reaction, chronic obstructive 
pulmonary diseases (COPD), lung disease, and pulmonary fibrosis 
[3]. Symptoms of this disease are chest illness, cough, and phlegm, 
shortness of breath [4]. The risk factors for CRDs include smoking, 
obesity, indoor air pollution, outdoor air pollution, unhealthy diet, 
lack of exercise, allergens, and biomass fuel combustion in low-
middle income countries (LMICs) [5]. 
In December of 2019, an epidemic origin from COVID-19 takes place 
in the Hubei Province of Wuhan, China. Up to 22nd
Pathogenesis 
 March 2020, the 
overall number of 306,506 cases of COVID-19 were turned up in 
hundreds of nations across the globe. As a beta coronavirus, SARS-
CoV-2 expose to danger the global health due to excessive mortality 
rates [6]. The zoonotic virus is not reviewed to be extremely 
infectious to living organisms up to the epidemic of a severe acute 
respiratory syndrome (SARS-CoV) in 2002 and 2003 respectively, in 
Guangdong province of China, was the coronavirus spread before 
the times in humans mainly give rise to a mild infection in immune-
competent peoples. Ten years later, SARS, a new and another 
dangerous pathogenic coronavirus, is the Middle East Respiratory 
Syndrome coronavirus (MERS-CoV) comes out in countries of 
middle east [7]. COVID-19 is one of the critical viruses that 
fundamentally select the respiratory system of living [8]. In late 
2019, a crowd of persons was divulged to their nearest hospitals 
with an untimely screening for pneumonia with an unspecified 
cause. Most of the persons were epidemiologically attached to the 
seafood and wet animal, vastly marketed in Wuhan [9, 10]. 
Coronavirus is swathe and single-stranded ribonucleic acid. The four 
major structural proteins hidden in the corona viral genome is the 
spike (S) protein that is linked to the angiotensin-converting 
enzyme-2 (ACE-2) receptor and arbitrates eventually attached 
between the swathe and host-cell membrane to encourage viral 
entrance into the host cells [11, 12]. As of 16 February 2020, the 
virus has given rise to a total of 70,548 infections in mainland China 
and Japan 413 infections [13]. This was the seventh known 
coronavirus, which gives rise to infection in humans [14]. Two other 
extraordinary examples SARS-C0V and MERS-C0V, previously which 
get down in Southern China and resulted in 8098 infections and 774 
deaths in 29 countries from 2002 to 2003 and then later on raised in 
Saudi Arabia and their it caused 2458 infections and 848 deaths in 
27 countries by 2019 [15, 16]. On 17 February 2020, the State 
Council of China clenched a news topic briefly which suggested that 
Chloroquine phosphate, a drug for the diagnosis of malaria, had 
revealed the mark of effective and acceptable safety in treating 
COVID-19 [17]. Chinese public health clinics and other scientific 
communities took immediate action for timely allow of the 
recognition of new pathogens and split the viral genome sequence 
across the globe [18]. SARS-CoV-2 is primarily spread from human 
contact or zoonotically to humans through respiratory droplets in 
contact with air, which is typically free in the through coughing or 
sneezing by an infected person. Most of the droplets from coughing 
or sneezing usually fall within a few meters of a person; this states 
that the probability of transmission is very low if each person 
maintains a distance of at least 2 meters [19]. The COVID-19 genetic 
sequence makes for the fast production of RT-PCR diagnostic point 
of care tests listed for 2019-nCoV [20].  
Coronavirus binds to the specific cellular receptors via the Virion 
spike (S) protein, this triggers the cell fusion of the spike into (S1 
and S2 domain) of the coronavirus, and it is accountable for the 
selection of the virus’s host tropism [21]. The subunits S1 and S2 
formed from the precursor cleavage, so S1 helps us to dictate 
tropism in cells and host’s viral range, and S2 is divided into heptad 
repeat 1 and heptad repeat 2 (HR1 and HR2), which helps in the 
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fusion of cell membrane and the pathogen. When HR1 binds with 
HR2 to form a six-helix bundle structure. This results in newer non-
infection indicated human contact transmission of the pathogen via 
air droplets by coughing, sneezing, or direct and indirect physical 
contact [22]. In this flow chart, we explained how the virus reached 
the host cell and the body reaction towards the virus [22, 23]. 
 
Coronaviridae family, Coronavirusinfection. (SARS-COV2) 
 
Enters in the human body zoonotically from bats, fellow humans 
 
ACE2 receptor binds with SARS-COV-2 present in organs like heart, lungs, kidneys, and GIT 
 
Attachment of virion spike (S) protein to ACE2 receptor in the cells of the host 
 
The fusion of spike protein (S1 and S2 domain) with the virus and host cell 
 
Type 2 transmembrane serine protease (TMPRSSZ) on surface host cells will clear the ACE2 receptor 
 
Activates the receptor to spike protein 
 
Conformational changes occur 
 
Allow the virus enters into the cells 
 
Release in the genome material in the cytoplasm of a cell and translated into nuclei 
 
Body’s immune response to SARS-CoV by mediating cytokines and decreases the total number of lymphocytes in the body. 
 
Symptoms 
COVID-19 patients may have symptomatic or asymptomatic 
coronavirus in them. After an incubation time of around 5.2 d, 
COVID-19 symptoms emerge [24]. There was between 6 and 41 d of 
onset of COVID-19 mortality symptoms and an average of 14 d. In 
patients>70 y it was shorter than in patients under 70 [25]. Fever, 
cough, tiredness are the most frequent symptoms of COVID-
19 onset, and diarrhea, headache, hemoptysis, and sputum are other 
symptoms [26-28].  
Increased number of leukocytes, irregular respiratory observations, 
and increased plasma levels of proinflammatory cytokines were 
reported by patients infected with COVID-19. In one of the COVID-19 
cases, a patient had a cough and a coarse lung coughing sound and a 
body temperature of 39.0 degrees Celsius at 5 d of fever [29].  
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Risk factors 
Patients which are at major risk for the progression of the disease, 
according to the researches it is confirmed that 87% of the people 
affected by COVID-19 were aged 30 to 79 y, almost half of such cases 
have one or more such severe health condition including diabetes, 
hypertension, cardiac diseases, and other such diseases condition 
which suppress the activity of immune system [22]. Smoking is 
assumed to generate adverse diseases related to the respiratory 
tract and also suppress the activity of the immune system [30]. 
Patients with hypertension as compared with healthy persons, have 
a higher affinity of facing severe conditions [31]. Patients suffering 
from diabetes mellitus have a greater risk of acquiring COVID-19. 
Type 2 diabetes is viewed as chronic, which leads to the imbalance 
of the immune system for a longer time, obesity with nutrient 
excess, or metabolic syndrome [32]. 
Treatment 
Radiological inspections are well known as essential in the early 
diagnosis and management of the coronavirus. Chest computed 
tomography can recognize the initial stage of lung poisoning and 
give rise to enormous citizen’s health supervision and retaliation 
system [33-35]. The incorporation of chest computed tomography 
for detection ensued in 14,840 authenticated latest instances 
reported on February 13, 2020. Nowadays, Realtime reverse 
transcription polymerase-chain-reaction (RT-PCR) evaluation for 
the pathogen is evolved and applied in hospitals [18]. RT-PCR is of 
prominent attentiveness nowadays for the recognition of SARS-CoV-
2 on accounts of its well-being as a determined and easy 
approximate analysis. Besides, real-time RT-PCR has sufficient 
responsiveness to assist us considerably in detecting premature 
contamination [36]. Even though RT-PCR remnants the attribution 
quality to produce a definition inspection of COVID contamination 
the big incorrect rejection grade and inconvenience of RT-PCR 
analysis in the premature phase of the outburst confined and give 
rise to the detection of diseased persons [37]. 
INF-alpha is an inclusive range antiviral agent that is mainly applied in 
the treatment of hepatitis however, it revealed to retard SARS-CoV 
breeding in vitro [38]. Ritonavir/lopinavir is a medicine that is used for 
the human immunodeficiency virus (HIV), generally given in amalgam 
along supplementary drugs to cure mature people and children above 
fourteen days of age those are suffering from HIV-1, it is also used in 
the SARS-CoV [39, 40]. Experts from China proposed that patients 
suffering from the virus pneumonia and not having a contraindication 
to chloroquine, be diagnosed with 500 mg two times a day for 10 d 
[41]. Hydroxychloroquine is illustrated as an anti-SARS-CoV effect in 
vitro. Its clinical assurance is preferable than that of chloroquine and 
permits a high daily dose and has little distress related to drug-drug 
interaction [42]. Chloroquine has vigorous anti-SARS-CoV outcomes in 
vitro, essentially referable to a deficiency at the surface of virus-cells in 
the glycosylation receptors, so that it may not be able to attach to the 
ACE 2 indicated in heart, lungs, kidneys, and intestines. SARS-CoV-2 
uses the analogous surface receptor ACE 2 glycosylation and helps in 
the prevention of SARS-COV-2 binding to the targeted cells [43, 44]. As 
the anatomy and mode of action of chloroquine and 
hydroxychloroquine are quite similar, excluding an extra hydroxyl 
group at an end of hydroxychloroquine, both function on a weekly 
basis that can change acid intracellular organs' pH, like 
endosomes/lysosomes, which are important for the fusion of 
membrane [45]. Convalescent plasma (CP) treatment, a best 
compatible treatment for the immune has been sued to safeguard and 
to cure many contagious afflictions from surpassing 100 y. CP 
treatment may be an encouraging therapy choice in COVID-19 rescues. 
Sufferers who have recorded from coronavirus with an elevated 
counteract antibody titer might be an important contributor to CP 
[46]. Targeting the trimer spike (S) glycoprotein at the surface of SARS-
CoV-2 that arbitrate entry into anchor cells can be counteracted by 
monoclonal antibodies [47]. The utilization of monoclonal antibodies is 
the latest period in contagious illness safeguards, which controls so 
many imperfections linked with serum treatment and intravenous 
immunoglobulin’s preparation concerning individuality, clarity, 
moderate threat of bloodborne pathogen infections, and welfare [48]. 
 
Vaccines 
Table 1: Provides the details about the list of vaccines for COVID-19 
Name Characteristics of vaccine Manufacturer Current status Reference 
mRNA-1273 S protein-encoding for LNP-encapsulated mRNA vaccine Moderna Phase I (NCT04283461) [49] 
Ad5-nCoV The S protein-expressing adenovirus type 5 vector. CanSino biologicals Phase I (NCT04313127) [49] 
INO-4800 S protein supplied by electroporation plasmid Encoding DNA Inovio pharmaceuticals Phase I (NCT04336410) [49] 
LV-SMENP-
DC 
Lentiviral vector modified DCs expressing synthetic 
minigenous on the basis of domains of selected viral 








Lentiviral Vector Modified aAPCs dependent on domains of 




Phase I (NCT04299724) [49] 
S protein-SARS-CoV-2 spike protein; LNP-lipid nanoparticle; DC-dendritic cell; CTL-cytotoxic T lymphocyte; aAPC-artificial antigen-presenting cell. 
 
 
Fig. 1: Information about coronavirus 
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Prevention 
COVID-19 infection is a zoonotically origin virus transmitted in 
human and also, it is a human-to-human transferrable disease, with 
an outbreak that is distributed all over the world. Patients which are 
affected by the virus should be isolated and the patient should be 
provided a single room for isolation. In severe medical conditions 
and to reduce the chance of contact with others, without late should 
refer to the clinical centers [50]. The patient should wear a proper 
mouth-covered mask and disposal of it properly. Maintaining 
distance socially by not having any type of physical contact may 
prevent the spread of diseases. For a stronger immune system by 
which we can prevent the coronavirus infection, we should consume 
healthy and nutritional food and should do regular exercise [51]. 
Management of diabetes during this pandemic 
Diabetes is one of the world's biggest death risk, with a dramatic 
spike in the age span in developed countries [52]. The international 
federation for diabetes records 415 million diabetes mellitus patients 
around the world [53]. Diabetes is a rapid procuring position of a 
developing pandemic in India; excess of sixty-two million patients of 
diabetes are presently suffering from the disease. India was in the top 
list in 2000 across the globe, followed by China and the US in terms of 
the highest diabetic patients [54]. The pancreas has two distinct 
components (i) acinar cells (ii) islets of Langerhans. There are at least 
four different types of cells in islets of Langerhans. Glucagon hormone 
is released from alpha cells. The beta cells release insulin. the secretion 
of insulin reduces the level of glucose in the blood, whereas secretion 
of glucagon increases it. Somatostatin secreted by delta cells, which 
hinders both glucagon and insulin [55]. Diabetes obtrudes a significant 
load to the community in the formation of inflated medical prices, 
previous productive capacity, transience, and ethereal prices in the 
form of a decreased grade of living [56]. Various pathogenic 
procedures are intricated in the expansion of diabetes. That ranges 
from autoimmune demolition of beta cells with successive insulin 
deficiencies to deformities that ensue obstruction in the action of 
insulin [57]. 
Diabetes is mainly of two types’ diabetes insipidus and diabetes 
mellitus. Diabetes insipidus is associated with the injury of 
neurohypophysis or its afferent neurosecretory cells arising from 
the supraoptic and paraventricular nuclei of the hypothalamus. 
Deformity of ADH is normally received as being responsible for the 
polyuria and diabetes insipidus [58]. Diabetes mellitus is a class of 
metabolic problems designated by hyperglycemia evolved from 
faults in insulin action, insulin release, or both. Symptoms of 
hyperglycemia are renal disorders; weight loss sometimes blurred 
vision [59]. Diabetes mellitus is the principal form of disease 
attributing to at least 90% of all cases of diabetes mellitus and 382 
million are affected by it across the globe as of 2013, and it is 
expected that it’ll affect more than 592 million by 2035 [60]. Obesity 
is the crucial danger aspect for diabetes; still, researches are going 
on across India [54]. To minimize the problem load created by 
diabetes in India proper government purposes and collaborative 
attempts from contributors of the civilization are necessary [61].  
Diabetes causes high septic course and serious pneumonia because 
of viral infection and happens in at least 20% of patients [62, 63]. 
Diabetes is supreme concurrent related to all 3 familiar people 
pathogenic coronavirus infection involving SARS-CoV-2. 20-50 
percent of sufferers from COVID have had diabetes. Generally, 
people suffering from all types of diabetes are at prone risk of 
getting contaminated because of their faults in cell-mediated 
immunity, innate immunity affecting phagocytosis, and neutrophil 
chemotaxis, though large constancy of diabetes in severe instances 
of coronavirus can throwback the inflated generality of type 2 
Diabetes Mellitus [64].  
In this epidemic, “Corona Virus Disease 2019” an individual having 
diabetes is more prone to vital ICU acceptance. Regulation of 
diabetes in the Intensive Care Unit is all time confronting, although 
the condition becomes more serious when the patients suffering 
from coronavirus have diabetes [65]. Recent researches also showed 
that COVID-19 is related to hyperglycemia, especially in older people 
having non-insulin-dependent diabetes [66]. The patients with 
preexisting type 2 diabetes experienced remarkable additional 
rigorous unified diagnosis to control indications of COVID-19 than 
the non-insulin-dependent diabetic issues [67]. Wuhan investigated 
in a review that on every side 10% of persons with type 2 diabetes 
and coronavirus always abided with a single part of hypoglycemia 
(<3.9 mmol/l) [68]. Diabetes mellitus is related to lessen assertion of 
ACE-2, an enzyme that is mostly articulated in the lungs, kidneys, 
intestines, and vascular endothelium [69]. Presymptomatic facts and 
fig. procured from reviewed established on previous SARS outburst 
(2003) suggested that COVID-19 may be accompanied to intensify 
management of glycemic in persons having diabetes mellitus that 
has generated due to stress of a serious disease [70]. Besides this, 
COVID-19 may cause inflamed insulin obstruction in humans with 
Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus. Gentle 
COVID-19 may produce a tendency to cause inflammation milieu as 
noticed by large numbers of Interleukin-6, Interleukin-1 beta, TNF-
alpha, monocyte, and inducible protein-10 that may cause a 
lowering of insulin obstructions. Furthermore, obesity is mainly 
connected to type 2 diabetes mellitus, which provokes the cytokine 
reaction and thus causes inflamed insulin obstructions [71].  
Tocilizumab is studied to enhance insulin obstructions and decrease 
HbA1C in persons suffering from diabetes mellitus and rheumatoid 
arthritis [72]. Camostat mesylate is commonly applied in the therapy 
of viral illness in opposition to COVID-19; the medicine was 
previously chased in the treatment of diabetes and it was observed 
to decrease levels of blood sugar in insulin-treated sufferers with 
diabetes [73]. Calcium channel blockers are observed to decline in 
the seriousness of disorders and transience in sufferers with 
pneumonia, likely to stop calcium reflux into the cell [74]. It is 
necessary to manage blood sugar levels in persons who are 
contaminated with the virus. Treatment of diabetes nowadays with 
the foundation on development is demanding; however, innovation 
like eHealth, telemedicine may be fruitful in this pandemic [75]. 
Diabetes management in this pandemic of Covid-19 can be 
controlled by keeping a few measures in mind. The former was to 
certify that primary diabetes facilities are procured and preserved in 
a period when there was a clepe for re-arrangement to maintain the 
necessity of common medical proficiency over secondary care 
facility. The latter was to give easy and secure diabetes guidelines to 
utilize by experts and non-expert’s diagnosis patients having or 
suspected of COVID-19 contamination [76]. The existence of 
diabetes rapidly perched out as a crucial danger part of enlarged 
humanity and morbidness from COVID-19 in China. For example, it 
was revealed that person sufferings from both diseases were 
remarkably further promising for vital regulation in the ICU with 
mechanical ventilation and eventually lead to death from the disease 
in contrast to them with acute COVID-19 without diabetes [77]. As 
stated in various reviews, the generality of diabetes in persons 
contaminated with the virus is identical as in the common 
community, although relatively lesser. An Italian researched 
supervised in 146 patients with committed SARS-CoV-2 
contamination at the University Hospital of Padova established a 
similar trend. The generality of diabetes in the patients was only 8.9 
percent, while it was 11 percent between the age group of 55–
75 from the same area in 2018 [78]. Diabetes is a metabolic 
condition that can be avoided by changes in lifestyle, nutrition, and 
overweight and obese regulation [79]. By the year 2030, its 
proportion will rise to 50% globally [80]. 
CONCLUSION 
Diabetes is among the rapidly-growing public health challenging 
diseases of the 21st century throughout the globe. Diabetes is 
generally growing very quickly in less-and middle earning countries 
than in high-earning countries. India is also known as the Diabetic 
capital of the world because of the high incidence of the disease. The 
current situation of the COVID-19 world pandemic gets worsens 
with each passing day. There is no vaccine developed for COVID-19 
till now, so it’s very important for people to boost their immunity 
and to take prevention. Early diagnosis can help diabetic patients to 
manage the disease. Diabetes is associated with the rising number 
and severity of COVID-19. For people suffering from both diseases, 
the morbidity is greater and those older significantly increased risk 
of death. It is necessary to maintain the blood sugar level of persons 
that are suffering from COVID-19. 
Hussain et al. 
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